Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?

@article{Langbein2019CombinedPU,
  title={Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?},
  author={Thomas Langbein and Hr Kulkarni and A. Singh and Coline Lehmann and Christiane Schuchardt and J Zhang and RP Baum},
  journal={57. Jahrestagung der Deutschen Gesellschaft f{\"u}r Nuklearmedizin},
  year={2019}
}
3 Citations

225Ac-PSMA-617 for Therapy of Prostate Cancer.

TLDR
Recently, de-escalated treatment protocols and application of 225Ac/177Lu-PSMA "cocktail"-regimens improved the tolerability of PSMA-TAT, reducing the risk for development dry-mouth syndrome, which opens new avenues for future application in earlier stage disease.